The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site.

All material subject to strictly enforced copyright laws. © 2020 Euromoney, a part of the Euromoney Institutional Investor PLC.

Fortune fails to favour the brave

Investors reacted unenthusiastically to Pfizer's plan to merge with rival US drug company Pharmacia, sending the shares 11% lower. It's not that the deal doesn't make sense but in today's volatile markets any bold move is frowned upon.

It's a measure of just how thin market activity has been this year that our league tables of M&A advisers for the first six months of 2002 have been knocked sideways by one big deal. When major deals are so few and far between, one transaction can make a huge difference to where the various institutions rank.


Pfizer's bid for Pharmacia, announced on July 15, represents $59.4 billion-worth of league table boost for Bear Stearns and Lazard Frères which are advising Pfizer, and for Goldman Sachs in the Pharmacia camp - assuming that nothing gets in the way of completion. No doubt those banks will be delighted to take the credit for arranging what is by far the biggest deal of 2002 so far.


Welcome back to mega-merger territory.



Take out a complimentary trial

Take out a 7 day trial to gain unlimited access to Euromoney.com and Asiamoney.com analysis and receive expertly-curated updates direct to your inbox.

 

Already a user?

Login now

 

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree